Early April, we look forward to sending a team of ExpreS²ion executives to the World Vaccine Congress in Washington D.C. The company's CSO Farshad Guirakhoo will be formally representing ExpreS²ion with a speech on Preclinical proof of concept for a novel VLP-based vaccine candidate for treatment of HER2+ breast cancers on April 3 at 12:25pm in the session on Cancer Immunotherapy.

Learn more on World Vaccine Congress Washington 2024